Viewing Study NCT05638594


Ignite Creation Date: 2025-12-25 @ 1:33 AM
Ignite Modification Date: 2025-12-26 @ 12:22 AM
Study NCT ID: NCT05638594
Status: RECRUITING
Last Update Posted: 2023-03-20
First Post: 2022-11-24
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
Sponsor: Shengjing Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module